Core Insights - The company aims to significantly enhance lives through RNA therapy delivery, reflecting a strong commitment to innovation in the healthcare sector [1] Company Development - Since its IPO five years ago, the company has progressed from having no clinical programs to currently having three programs in late-stage development, indicating substantial growth and advancement in its research and development efforts [1]

Avidity Biosciences (RNA) FY 2025 Conference September 04, 2025 12:45 PM ET Company ParticipantsKathleen Gallagher - Chief Program OfficerMichael MacLean - CFOConference Call ParticipantsYanan Zhu - Senior Analyst - Biotechnology Equity ResearchYanan ZhuGreat. Thanks, everyone, for being here. My name is Yan Andriu. I'm one of the biotech analysts here at Wells Fargo. It is our great privilege to have the Avidity Biosciences management team here for Fireside Chat. With me on stage, CFO Mike MacLean and Kath ...